Tirzepatide achieves noninferiority to dulaglutide for cardiovascular outcomes in T2D with ASCVD
Background
Patients with type 2 diabetes (T2D), especially those with established atherosclerotic cardiovascular disease (ASCVD), face a significantly elevated risk of major adverse cardiovascular events (MACEs). While traditional GLP-1 receptor agonists (GLP-1RAs) have demonstrated efficacy in reducing these events, there's a continuous drive for therapies offering enhanced glycemic control and broader metabolic benefits. Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, has shown superior glucose and weight management compared to existing GLP-1RAs. This study aimed to determine if these additional benefits translate into comparable or superior cardiovascular protection.
Study Design
The SURPASS-CVOT trial, a randomized clinical trial, investigated the cardiovascular safety and efficacy of tirzepatide compared to dulaglutide in adults diagnosed with type 2 diabetes and established atherosclerotic cardiovascular disease. Participants were randomized to receive either tirzepatide or dulaglutide for a median duration of 4 years. The primary endpoint was a composite of major adverse cardiovascular events (MACEs), which included cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. The study was designed as a non-inferiority trial to assess if tirzepatide was at least as effective as dulaglutide in preventing MACEs.
Results
In adults with type 2 diabetes and ASCVD, tirzepatide demonstrated noninferiority to dulaglutide regarding the primary composite cardiovascular outcome. Non-inferiority was successfully met with a statistically significant p-value of p = 0.003. However, the trial did not achieve statistical superiority for tirzepatide over dulaglutide for the primary endpoint, with a hazard ratio (HR) of 0.92 (95% confidence interval [CI] 0.83 to 1.01; P = 0.09). This indicates that while tirzepatide was not worse than dulaglutide for MACE reduction, it did not show a statistically significant improvement. > Several secondary endpoints, which likely included measures of glycemic control and weight reduction, tended to favor tirzepatide, reinforcing its known metabolic advantages.
Key Findings
- Tirzepatide was noninferior to dulaglutide for composite CV outcomes in T2D and ASCVD.
- Non-inferiority for MACEs was statistically significant (p = 0.003).
- Superiority of tirzepatide for MACEs was not met (HR 0.92; 95% CI 0.83-1.01; P = 0.09).
- The study duration was a median of 4 years, providing long-term data.
Why It Matters
For individuals managing type 2 diabetes and ASCVD, tirzepatide now stands as a robust option for cardiovascular risk reduction, demonstrating comparable efficacy to the established GLP-1RA dulaglutide. This finding expands the therapeutic arsenal, offering clinicians and patients another powerful tool for comprehensive diabetes and cardiovascular management. Given tirzepatide's known superior effects on glycemic control and body weight, its noninferiority for MACEs makes it a compelling choice, potentially allowing for a single agent to address multiple critical health parameters. While not superior for MACEs, its overall metabolic profile could lead to better long-term outcomes and simplify treatment regimens for many.
tirzepatide
dulaglutide
type-2-diabetes
ascvd
cardiovascular-disease
glp-1-agonist